Eli Lilly shared early clinical data on the BTK inhibitor it acquired with Loxo Oncology—and the numbers have Lilly outlining plans for “an ambitious comprehensive development program."
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,